JUNE 17, 2021

Next©ure

Next-Generation Immunomedicines


The JMP Securities Life Sciences Conference

Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statements under the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "next," "near-term," "future" and similar expressions, as well as other words and expressions referencing future events, conditions, or circumstances, are intended to identify forward-looking statements. Examples of forward-looking statements in this presentation may include, among others, statements regarding: (i) the timing, progress and results of our preclinical and clinical trials; (ii) the evaluation of biomarkers; (iii) the impact of the COVID-19 pandemic on the initiation, progress or expected timing of those trials and the timing of related data, as well as our efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic; (iv) the timing or likelihood of regulatory filings for our product candidates; (v) our manufacturing capabilities and strategy; (vi) the potential benefits and activity of our product candidates; (vii) our expectations regarding the nature of the biological pathways we are studying; (viii) our expectations regarding our FIND-IO platform; and (ix) the potential benefits of our relationships with Dr. Lieping Chen and Yale University.

Various factors could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impact of the ongoing COVID-19 pandemic on our business, including our clinical trials, third parties on which we rely and our operations; our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. For further discussion of these and other factors that could affect the outcome of our forward-looking statements, see our filings with the Securities and Exchange Commission, including in "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Risk Factors section and throughout NextCure's Form 10-K filed with the SEC on May 6, 2021. Except as otherwise indicated, this presentation speaks as of the date indicated herein. Except as required by law, we assume no obligation to update any forward-looking statements, even if new information becomes available in the future. The information in this presentation is not complete and may be changed.

Next©ure



Product Development Pipeline

PROGRAMS	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONE	WORLDWIDE RIGHTS
PRODUCT CANDIDATES								
NC318 (S15) Monotherapy	Tumors and macrophages	ONCOLOG	δY				Report update 4Q 2021	Next© ure
NC318 (S15) Anti-PD-1 Combo*	Tumors and macrophages	ONCOLOG	δY				Initial data 1H 2022	Next© ure
NC410 (LAIR-1)	Dendritic and T cells	ONCOLOG	SΥ				Initial data 2H 2021	Next© ure
NC762 (B7-H4)	Tumors	ONCOLOG	GΥ				Start Phase 1 2Q 2021	Next© ure

DISCOVERY AND RESEARCH PROGRAMS


Multiple Programs	Multiple cell types				IND filing in 2022	Next© ure
-------------------	------------------------	--	--	--	-----------------------	------------------

*Investigator-initiated (IIT) trial (Yale University)




NC318 Humanized Siglec-15 (S15) Monoclonal Antibody







NC318 Phase 1/2 Monotherapy Trial Status as of March 4, 2021

















Yale Investigator-Initiated Phase 2 Trial in Non-Small Cell Lung Cancer



NCT04699123



Selecting S15 Positive Patients for NC318 Study








NC410 Decoy Human Fusion Protein Targeting the TME



BIOLOGY

- Dendritic cells and T cells
- Advanced or metastatic cancers
 - NSCLC
 - Ovarian cancer
 - Pancreatic cancer



UPDATE

- Extracellular matrix remodeling
- Enhances T cell infiltration and tumor killing
- Synergistic combinations
- ASCO 2021 poster




LAIR-1 & LAIR-2 Functional Relationship

LAIR & LIGANDS

LAIR-1 and LAIR-2 Bind Collagen and C1q


NC410 IS A FUSION PROTEIN OF LAIR-2

Decoy for LAIR-1 and promotes T cell function and DC activation





NC410 Phase 1 Portion of Phase 1/2 First-in-Human Trial



NATIONAL CANCER INSTITUTE Center for Cancer Research John Theurer Cancer Center at Hackensack University Medical Center MDAnderson Cancer Center




NC762 Humanized B7-H4 Monoclonal Antibody



BIOLOGY

- Inhibits tumor cell growth and is not dependent on T cells
- NK cells enhance anti-tumor activity
- Advanced or metastatic cancers
 - NSCLC
 - Breast cancer
 - Ovarian cancer

MOA



₱ B7-H4 ▼NC762 (B7-H4 mAb)

UPDATE

• IND filed

- Unique mechanism of action
- IHC assay for patient selection
- Biomarkers
- Phase 1 2Q 2021
- AACR 2021 poster




GMP Manufacturing Facility: Added Additional Capacity



Utilized to Produce Clinical Material for All Lead Programs



FIND-IO: Finding Solutions with a Powerful Discovery Engine





Anticipated Near-Term Milestones

	Cash Positi	on: \$268.2N	1 Runw	vay: 2H 2023				
	2021				2022			
PROGRAMS	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
PRODUCT CANDIDATES								
NC318 (S15) Monotherapy				Phase 2 update				
NC318 (S15) Anti-PD-1 Combo*		Start Phase 2			Anticipate	initial data		
NC410 (LAIR-1)				Initial data				
NC762 (B7-H4)		Start Phase 1			Initial data			

*Investigator-initiated (IIT) trial (Yale University)



Next©ure



Committed to Addressing the Unmet Needs of Patients with New Solutions

FOCUSED Approach PROVEN Momentum

INNOVATIVE Platform EXPERIENCED Team **FUTURE** Deliverables